Genomic Predictors of Outcome in Prostate Cancer

被引:135
作者
Bostrom, Peter J. [1 ]
Bjartell, Anders S. [2 ]
Catto, James W. F. [3 ]
Eggener, Scott E. [4 ]
Lilja, Hans [5 ,6 ,7 ,8 ,9 ]
Loeb, Stacy [10 ,11 ]
Schalken, Jack [12 ]
Schlomm, Thorsten [13 ]
Cooperberg, Matthew R. [14 ,15 ]
机构
[1] Turku Univ Hosp, Dept Urol, FIN-20520 Turku, Finland
[2] Lund Univ, Skane Univ, Dept Urol, Hosp Malmo, Lund, Sweden
[3] Univ Sheffield, Acad Urol Unit, Sheffield, S Yorkshire, England
[4] Univ Chicago, Urol Sect, Chicago, IL 60637 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Lab Med, New York, NY 10021 USA
[6] Mem Sloan Kettering Canc Ctr, Dept Surg Urol, New York, NY 10021 USA
[7] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[8] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England
[9] Univ Tampere, Inst Biomed Technol, FIN-33101 Tampere, Finland
[10] NYU, Dept Urol & Populat Hlth, New York, NY USA
[11] Manhattan Vet Affairs Med Ctr, New York, NY USA
[12] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 ED Nijmegen, Netherlands
[13] Univ Med Ctr Hamburg Eppendorf, Prostate Canc Ctr, Martini Clin, Hamburg, Germany
[14] UCSF Helen Diller Family Comprehens Canc, Dept Urol, San Francisco, CA USA
[15] UCSF Helen Diller Family Comprehens Canc, Dept Epidemiol & Biostat, San Francisco, CA USA
关键词
Prostate cancer; Prognostic; Predictive; Outcome; Gene panel; Expression panel; Genetic test; RNA; Cell cycle; DNA; TMPRSS2-ERG GENE FUSION; CYCLE PROGRESSION SCORE; ERG PROTEIN EXPRESSION; HIGH-RISK; ACTIVE SURVEILLANCE; PROGNOSTIC VALUE; PSA RECURRENCE; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; SYSTEMIC PROGRESSION;
D O I
10.1016/j.eururo.2015.04.008
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Context: Given the highly variable behavior and clinical course of prostate cancer (PCa) and the multiple available treatment options, a personalized approach to oncologic risk stratification is important. Novel genetic approaches offer additional information to improve clinical decision making. Objective: To review the use of genomic biomarkers in the prognostication of PCa outcome and prediction of therapeutic response. Evidence acquisition: Systematic literature review focused on human clinical studies reporting outcome measures with external validation. The literature search included all Medline, Embase, and Scopus articles from inception through July 2014. Evidence synthesis: An improved understanding of the genetic basis of prostate carcinogenesis has produced an increasing number of potential prognostic and predictive tools, such as transmembrane protease, serine2: v-ets avian erythroblastosis virus E26 oncogene homolog (TMPRSS2: ERG) gene fusion status, loss of the phosphatase and tensin homolog (PTEN) gene, and gene expression signatures utilizing messenger RNA from tumor tissue. Several commercially available gene panels with external validation are now available, although most have yet to be widely used. The most studied commercially available gene panels, Prolaris, Oncotype DX Genomic Prostate Score, and Decipher, may be used to estimate disease outcome in addition to clinical parameters or clinical nomograms. ConfirmMDx is an epigenetic test used to predict the results of repeat prostate biopsy after an initial negative biopsy. Additional future strategies include using genetic information from circulating tumor cells in the peripheral blood to guide treatment decisions at the initial diagnosis and at subsequent decision points. Conclusions: Major advances have been made in our understanding of PCa biology in recent years. Our field is currently exploring the early stages of a personalized approach to augment traditional clinical decision making using commercially available genomic tools. A more comprehensive appreciation of value, limitations, and cost is important. Patient summary: We summarized current advances in genomic testing in prostate cancer with a special focus on the estimation of disease outcome. Several commercial tests are currently available, but further understanding is needed to appreciate the potential benefits and limitations of these novel tests. (C) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1033 / 1044
页数:12
相关论文
共 100 条
[91]   Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer [J].
Tomlins, SA ;
Rhodes, DR ;
Perner, S ;
Dhanasekaran, SM ;
Mehra, R ;
Sun, XW ;
Varambally, S ;
Cao, XH ;
Tchinda, J ;
Kuefer, R ;
Lee, C ;
Montie, JE ;
Shah, RB ;
Pienta, KJ ;
Rubin, MA ;
Chinnaiyan, AM .
SCIENCE, 2005, 310 (5748) :644-648
[92]   ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice [J].
Tomlins, Scott A. ;
Bjartell, Anders ;
Chinnaiyan, Arul M. ;
Jenster, Guido ;
Nam, Robert K. ;
Rubin, Mark A. ;
Schalken, Jack A. .
EUROPEAN UROLOGY, 2009, 56 (02) :275-286
[93]   Global Cancer Statistics, 2012 [J].
Torre, Lindsey A. ;
Bray, Freddie ;
Siegel, Rebecca L. ;
Ferlay, Jacques ;
Lortet-Tieulent, Joannie ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2015, 65 (02) :87-108
[94]   Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer [J].
Tsuchiya, N ;
Slezak, JM ;
Lieber, MM ;
Bergstralh, EJ ;
Jenkins, RB .
GENES CHROMOSOMES & CANCER, 2002, 34 (04) :363-371
[95]   Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens [J].
Vaananen, Riina-Minna ;
Lilja, Hans ;
Kauko, Leni ;
Helo, Pauliina ;
Kekki, Henna ;
Cronin, Angel M. ;
Vickers, Andrew J. ;
Nurmi, Martti ;
Alanen, Kalle ;
Bjartell, Anders ;
Pettersson, Kim .
UROLOGY, 2014, 83 (02) :511.e1-511.e7
[96]   Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer [J].
Weischenfeldt, Joachim ;
Simon, Ronald ;
Feuerbach, Lars ;
Schlangen, Karin ;
Weichenhan, Dieter ;
Minner, Sarah ;
Wuttig, Daniela ;
Warnatz, Hans-Joerg ;
Stehr, Henning ;
Rausch, Tobias ;
Jaeger, Natalie ;
Gu, Lei ;
Bogatyrova, Olga ;
Stuetz, Adrian M. ;
Claus, Rainer ;
Eils, Juergen ;
Eils, Roland ;
Gerhaeuser, Clarissa ;
Huang, Po-Hsien ;
Hutter, Barbara ;
Kabbe, Rolf ;
Lawerenz, Christian ;
Radomski, Sylwester ;
Bartholomae, Cynthia C. ;
Faelth, Maria ;
Gade, Stephan ;
Schmidt, Manfred ;
Amschler, Nina ;
Hass, Thomas ;
Galal, Rami ;
Gjoni, Jovisa ;
Kuner, Ruprecht ;
Baer, Constance ;
Masser, Sawinee ;
von Kalle, Christof ;
Zichner, Thomas ;
Benes, Vladimir ;
Raeder, Benjamin ;
Mader, Malte ;
Amstislavskiy, Vyacheslav ;
Avci, Meryem ;
Lehrach, Hans ;
Parkhomchuk, Dmitri ;
Sultan, Marc ;
Burkhardt, Lia ;
Graefen, Markus ;
Huland, Hartwig ;
Kluth, Martina ;
Krohn, Antje ;
Sirma, Hueseyin .
CANCER CELL, 2013, 23 (02) :159-170
[97]  
Wojno KJ, 2014, AM HEALTH DRUG BENEF, V7, P129
[98]   Development and validation of a 32-gene prognostic index for prostate cancer progression [J].
Wu, Chin-Lee ;
Schroeder, Brock E. ;
Ma, Xiao-Jun ;
Cutie, Christopher J. ;
Wu, Shulin ;
Salunga, Ranelle ;
Zhang, Yi ;
Kattan, Michael W. ;
Schnabel, Catherine A. ;
Erlander, Mark G. ;
McDougal, W. Scott .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (15) :6121-6126
[99]   Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome [J].
Yoshimoto, Maisa ;
Joshua, Anthony M. ;
Cunha, Isabela W. ;
Coudry, Renata A. ;
Fonseca, Francisco P. ;
Ludkovski, Olga ;
Zielenska, Maria ;
Soares, Fernando A. ;
Squire, Jeremy A. .
MODERN PATHOLOGY, 2008, 21 (12) :1451-1460
[100]   Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy [J].
Zafarana, Gaetano ;
Ishkanian, Adrian S. ;
Malloff, Chad A. ;
Locke, Jennifer A. ;
Sykes, Jenna ;
Thoms, John ;
Lam, Wan L. ;
Squire, Jeremy A. ;
Yoshimoto, Maisa ;
Ramnarine, Varune Rohan ;
Meng, Alice ;
Ahmed, Omar ;
Jurisca, Igor ;
Milosevic, Michael ;
Pintilie, Melania ;
van der Kwast, Theo ;
Bristow, Robert G. .
CANCER, 2012, 118 (16) :4053-4062